Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.

Nakai T, Sakai D, Nakamura Y, Horikita N, Matsushita E, Naiki M, Watanabe M.

Open source

DOI
10.1186/s12920-021-00926-x
Published
2021-03-11
Container
BMC Med Genomics
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12920-021-00926-x,
  title = {Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.},
  author = {Nakai T and  Sakai D and  Nakamura Y and  Horikita N and  Matsushita E and  Naiki M and  Watanabe M.},
  year = {2021},
  journal = {BMC Med Genomics},
  doi = {10.1186/s12920-021-00926-x},
  url = {https://doi.org/10.1186/s12920-021-00926-x}
}

RIS

TY  - JOUR
TI  - Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.
AU  - Nakai T
AU  -  Sakai D
AU  -  Nakamura Y
AU  -  Horikita N
AU  -  Matsushita E
AU  -  Naiki M
AU  -  Watanabe M.
PY  - 2021
JO  - BMC Med Genomics
DO  - 10.1186/s12920-021-00926-x
UR  - https://doi.org/10.1186/s12920-021-00926-x
ER  - 

APA

T, N., D, S., Y, N., N, H., E, M., M, N., & M., W. (2021). Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study.. BMC Med Genomics. https://doi.org/10.1186/s12920-021-00926-x

Source records